PaxMedica, Inc., wani kamfani na biopharmaceutical da ke mayar da hankali kan haɓaka magungunan da ke taimakawa wajen shawo kan ƙalubalen rayuwa tare da mawuyacin yanayi, a yau ya sanar da cewa ya sami amincewa daga Hukumar Kula da Kayayyakin Lafiya ta Afirka ta Kudu (SAHPRA) don aikace-aikacen gwaji na asibiti don nazarin Sakamakon PAX-101 (suramin intravenous (IV) infusions) a cikin marasa lafiya tare da Dogon COVID-19 Syndrome (LCS), wanda kuma aka sani da cututtukan cututtukan cututtukan SARS-CoV-2.
Nazarin, PAX-LCS-101, zai zama Mataki na 1B, mai yiwuwa, bazuwar, sarrafa wuribo, makafi biyu, nazarin kashi-kashi da yawa. Ana sa ran binciken zai fara rajistar marasa lafiya a cikin rubu'in farko na wannan shekara bayan samun amincewar kwamitin da'a na Afirka ta Kudu.
LCS cuta ce mai tsanani, cuta mai nau'i-nau'i wanda ke haifar da babban lahani na aiki a cikin mutane da yawa bayan kamuwa da cuta mai tsanani tare da COVID-19. Sakamakon ganewar LCS yana da ƙalubale saboda babu takamaiman gwaje-gwaje don tabbatar da ganewar asali. Kodayake akwai ma'anoni da yawa da aka tsara a cikin wallafe-wallafen likitanci, yawancin masu bincike suna bayyana LCS a matsayin ciwo wanda ya haɗa da tsawon lokaci na nau'o'in bayyanar cututtuka na jiki da na neuropsychiatric da ke ci gaba har tsawon makonni 12 ko fiye ba tare da wani bayani ba. Ana sa ran binciken zai yi rajistar marasa lafiya tare da alamun ci gaba da alamun LCS, bayan kamuwa da cuta da aka rubuta a baya tare da kwayar COVID-19. Alamun LCS a cikin kowane mai haƙuri na iya bambanta amma sau da yawa sun haɗa da gajiya, "hazo na kwakwalwa", zafi, ciwon kai, ƙarancin numfashi, wahala tare da maida hankali da hankali, damuwa barci, orthostasis da dizziness, da rage aiki da kuma yawancin alamun da ke hade da su. kamar ciwon haɗin gwiwa da tsoka, damuwa da damuwa.
An lura da LCS don yayi kama da wani cuta mai saurin kamuwa da cuta wanda aka sani da myalgic encephalomyelitis / ciwon gajiya mai tsanani (ME/CFS). A cikin duka rikice-rikicen, gajiya fitacciyar alama ce kuma yawancin sauran alamun da aka gani sun zo juna. Dukansu yanayi na iya haifar da rashin iya aiki ko yin ayyukan al'ada kuma a cikin matsanancin yanayi na ME/CFS, an rubuta su don ɗorewa na shekaru, wanda ya haifar da waɗanda abin ya shafa sun zama gida-, idan ba a daure ba. PaxMedica yana shirin yin nazarin PAX-101 a matsayin magani ga LCS da ME/CFS.
An shirya wannan gwaji na asibiti don nazarin aminci da haƙuri, inganci, da PK na nau'i biyu na suramin (5 mg / kg da 10 mg / kg) a cikin manya, 18 shekaru da haihuwa, tare da LCS.
Duk da mahimmancin buƙatun likita na jiyya na LCS, babu wasu magunguna da aka yarda da su a halin yanzu don wannan cuta. Akwai haɓaka yarjejeniya a cikin al'ummomin kimiyya da na likitanci game da buƙatar ƙarin bincike kan abubuwan da ke haifar da LCS, da kuma cutar da ke da alaƙa da ME/CFS
PAX-101 kuma a halin yanzu yana cikin Mataki na 2 don Cutar Autism Spectrum ("ASD"). Har ila yau, Kamfanin yana haɓaka PAX-102, wani nau'in na'ura na cikin ciki na suramin, don ASD da sauran cututtukan neurologic.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- , a biopharmaceutical company focused on developing medicines that help overcome the challenges of living with complex neurological conditions, today announced that it has received approval from the South African Health Products Regulatory Agency (SAHPRA) for its clinical trial application to study the effects of PAX-101 (suramin intravenous (IV) infusions) in patients with Long COVID-19 Syndrome (LCS), also known as post-acute sequelae of SARS-CoV-2 infection.
- The symptoms of LCS in each patient can vary but often include fatigue, “brain fog”, pain, headaches, shortness of breath, difficulty with concentration and attention, sleep disturbance, orthostasis and dizziness, and decreased functioning as well as many associated symptoms such as joint and muscle pain, depression and anxiety.
- Although there are many definitions proposed in the medical literature, most researchers define LCS as a syndrome that includes a protracted course of various physical and neuropsychiatric symptoms that persist for 12 weeks or more without an alternative explanation.
